22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease.
Merck Research Laboratories
Peptide-based inhibitors of the hepatitis C virus serine protease.
Boehringer Ingelheim (Canada)
Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis.
Children's Hospital Affiliated to Zhengzhou University
2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.
Bristol-Myers Squibb Research & Development
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.
Bristol Myers Squibb Research and Early Development
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
Second Military Medical University
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
Vertex Pharmaceuticals
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Vertex Pharmaceuticals
Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.
University of Massachusetts Medical School
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.
Vertex Pharmaceuticals
Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.
Mrl Rome
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
Glaxosmithkline
Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.
Irbm, Mrl Rome
A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.
Irbm, Mrl Rome
The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.
Roche Discover Welwyn
Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
Boehringer Ingelheim (Canada)
A review on HCV inhibitors: Significance of non-structural polyproteins.
Institute of Pharmaceutical Education and Research
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
Bristol-Myers Squibb Research and Development
Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants.
University of Massachusetts Medical School